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background:  The DAPT trial evaluated the role of longer-term dual antiplatelet therapy (DAPT) with either clopidogrel or prasugrel 
following percutaneous coronary intervention with drug-eluting stents (DES). However, ticagrelor has not been studied beyond 12 months 
of therapy. We sought to ascertain if there might be a benefit with longer-term DAPT with ticagrelor assuming constant estimates of 
ischemic benefit and bleeding risk beyond the first 12 months.
methods:  We developed a decision-analytic Markov model comparing DAPT durations of 12 and 30 months after DES in acute coronary 
syndrome. Published studies were used to derive the probabilities for stent thrombosis (ST), myocardial infarction (MI), cardiac and non-
cardiac death, major and minor bleeding, and hemorrhagic and ischemic stroke. Relative risks (RR) of the benefit and risk of ticagrelor over 
clopidogrel were derived from the invasive sub-study of the PLATO trial and rates beyond the 12 months were assumed to be constant. 
The outcome from each strategy was quantified in terms of quality-adjusted life years (QALY). Sensitivity analyses were performed to 
address uncertainty in the data and to identify the reduction in ST or the composite of cardiac death, myocardial infarction and ischemic 
stroke (MACCE; components varied equally) that would be required to outweigh the increased risk of bleeding associated with longer 
DAPT.
results:  Assuming constant benefit and bleeding risk of ticagrelor beyond 12 months, 30 months of DAPT with ticagrelor was found to be 
superior to 12 months of therapy (13.4658 vs. 13.3607 QALYs), largely driven by the reduction in the rate of cardiac death with ticagrelor 
over clopidogrel. In sensitivity analyses, assuming no difference in the rate of long-term cardiac death between ticagrelor and clopidogrel, 
a RR reduction of 46% (absolute risk reduction, ARR, 0.30%) in ST, and 2.5% (ARR 0.76%) in MACCE would be required for 30-months of 
DAPT with ticagrelor to be preferred over 12-months of therapy.
Conclusion:  Adequately powered randomized trials are required to determine whether longer-duration DAPT with ticagrelor is associated 
with reductions in ST or MACCE that outweigh the impact of bleeding.
